HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $68
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Halozyme Therapeutics and raised the price target from $65 to $68, indicating a positive outlook for the company's stock.
November 01, 2024 | 11:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Halozyme Therapeutics and increased the price target from $65 to $68, suggesting a positive short-term outlook for the stock.
The analyst's decision to maintain a Buy rating and raise the price target indicates confidence in Halozyme's future performance, likely leading to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100